Detalhe da pesquisa
1.
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Lancet HIV
; 9(8): e534-e543, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905752
2.
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Lancet Haematol
; 6(7): e375-e383, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31201085